Current Report Filing (8-k)
October 04 2019 - 4:11PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act Of 1934
Date of Report (Date of earliest event reported):
October 1, 2019
___________________________________________________________
ACURA PHARMACEUTICALS, INC.
(Exact Name of Registrant as specified in
its Charter)
___________________________________________________________
New York
|
1-10113
|
11-0853640
|
(State of Other Jurisdiction
|
(Commission File Number)
|
(I.R.S. Employer
|
of Incorporation)
|
|
Identification Number)
|
616 N. North Court, Suite 120
Palatine, Illinois 60067
(847) 705-7709
(Address, Including Zip Code, and Telephone
Number, Including Area Code, of Registrant’s Principal Executive Offices)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, $0.01 par value
|
|
ACUR
|
|
OTC – PINK
|
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions):
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d- 2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e- 4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging Growth Company
¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02 - Results of Operations and Financial Condition
On September 30, 2019, Acura Pharmaceuticals,
Inc. issued a press release announcing its financial results for its first quarter ended March 31, 2019. A copy of that press release
and the attached financial schedules are attached as Exhibit 99.1 to this report and incorporated herein by reference.
Item 9.01 - Financial Statements and Exhibits
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: October 1, 2019
|
ACURA PHARMACEUTICALS, INC.
|
|
|
|
|
|
By:
|
/s/ Peter A. Clemens
|
|
|
Peter A. Clemens
|
|
|
Senior Vice President & Chief Financial Officer
|
Acura Pharmaceuticals (CE) (USOTC:ACUR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Acura Pharmaceuticals (CE) (USOTC:ACUR)
Historical Stock Chart
From Sep 2023 to Sep 2024